11:52:58 Europe / Stockholm


2023-03-01 14:40:00

Redeye provides an update in relation to ISAB’s Q4 2022 report. Full-year sales came in at SEK12.2m (SEK9.4m) and EBIT at SEK-12.0m (SEK-16.6m). We have chosen to make some changes in our model, mainly changes in sales and OPEX, and included an equity issue during 2023. This results in a new fair value range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/